Volume 30, Number 7—July 2024
Research Letter
Plasmodium vivax Infections among Immigrants from China Traveling to the United States
Paloma Khamly
, Nahel Kapadia, Minette Umali-Wilcox, Susan M. Butler-Wu, and Kusha Davar
, Nahel Kapadia, Minette Umali-Wilcox, Susan M. Butler-Wu, and Kusha Davar
Table
Characteristics and treatment regimens of patients with diagnosed Plasmodium vivax infections among immigrants from China traveling to the United States via Central and South America, Los Angeles, California, USA, January 2023–April 2024*
| Case no. | Date diagnosed | Clinical signs and symptoms | Duration of symptoms | % Parasitemia | Outpatient vs. inpatient | Treatment | Antirelapse treatment |
|---|---|---|---|---|---|---|---|
| Case 1 |
Mar 2023 |
Fever, chills, myalgias, shortness of breath |
2 mo |
0.10% |
Inpatient |
HCQ |
Primaquine |
| Case 2 |
Mar 2023 |
Fever, diaphoresis, nausea |
1.5 mo |
0.30% |
Inpatient |
AP |
Primaquine |
| Case 3 |
May 2023 |
Fever, fatigue, myalgias |
9 d |
<0.20% |
Outpatient |
AP |
Primaquine |
| Case 4 |
Jun 2023 |
Fever, chills |
1 wk |
0.13% |
Outpatient |
Chloroquine |
Primaquine |
| Case 5 |
Sept 2023 |
Fever, headache, diarrhea, nausea, vomiting |
1 wk |
0.05% |
Outpatient |
AP |
Primaquine |
| Case 6 |
Jan 2024 |
Fever, cough |
10 d |
<0.20% |
Outpatient |
AP |
Primaquine |
| Case 7 |
Jan 2024 |
Fever, chills, myalgias, nausea |
10 d |
<0.20% |
Inpatient |
AP |
Primaquine |
| Case 8 |
Jan 2024 |
Fever, chills, myalgias |
10 d |
0.20%–1.0% |
Inpatient |
AP |
Primaquine |
| Case 9 | Jan 2024 | Fever, chills, fatigue, cough | 4 d | 0.20%–1.0% | Inpatient | Chloroquine | Primaquine |
*All patients met criteria for uncomplicated malaria. AP, atovaquone/proguanil; HCQ, hydroxychloroquine.
Page created: May 02, 2024
Page updated: June 22, 2024
Page reviewed: June 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.